Brachytherapy Results for Low- and Intermediate-risk Prostate Cancer Treated at Mayo Clinic

According to a retrospective study published this month in the journal Brachytherapy,  permanent low-dose-rate (LDR)  prostate brachytherapy monotherapy with I-125 has worked well for men with low-and intermediate-risk prostate cancer.

Investigating outcomes for a series of 974 patients treated at the Mayo with this type of permanent “seed” implant brachytherapy  analysts focused on factors associated with biochemical failure and survival. Continue reading “Brachytherapy Results for Low- and Intermediate-risk Prostate Cancer Treated at Mayo Clinic”

Androgen-deprivation therapy before radical surgery for prostate cancer may harm a subset of patients, help others, study suggests

A study from Japan suggests that men should probably avoid androgen blockade before prostate surgery if they are above 65 or have low testosterone levels.

This round of treatment, known as neoadjuvant ADT, may be prescribed with a view to improving odds for patients who have some adverse markers.

Led by  Prof. Masatoshi Eto, the Japanese team analyzed results for 711 patients with clinically localized prostate cancer who were treated with radical prostatectomy (RP) between 2000 and 2013. Some patients underwent androgen deprivation therapy before the surgery, some did not. Continue reading “Androgen-deprivation therapy before radical surgery for prostate cancer may harm a subset of patients, help others, study suggests”